Question 1

What is ICD-10 code M90.611?

Accepted Answer

M90.611 is the ICD-10-CM diagnosis code for osteitis deformans in neoplastic diseases, right shoulder. Bone deformity and inflammation in the right shoulder caused by cancer or tumor-related disease. M90.611 sits in the ICD-10-CM chapter for diseases of the musculoskeletal system and connective tissue (m00-m99), within the section covering other osteopathies (m86-m90).

M90.611 is a billable ICD-10-CM code but does not map to a payment HCC under the CMS-HCC V28, V24, ESRD, or RxHCC risk adjustment models. It can be reported on Medicare Advantage encounter data submissions but it does not contribute to a beneficiary's RAF score and therefore does not affect risk-adjusted payments to the plan.

This code requires documentation of the underlying neoplastic disease; code the primary malignancy separately.

Question 2

Is M90.611 an HCC code?

Accepted Answer

No. M90.611 is a billable ICD-10-CM code but does not map to any payment HCC category under the CMS-HCC V28, V24, ESRD, or RxHCC risk adjustment models. It can still be reported on Medicare Advantage encounter data submissions, but it does not contribute to the beneficiary's Risk Adjustment Factor (RAF) score and therefore does not affect the risk-adjusted capitation payment to the plan. V28 reached 100% phase-in for payment year 2026.

Question 3

Is M90.611 billable?

Accepted Answer

Yes. M90.611 is a billable ICD-10-CM code that can be reported on professional and institutional claims as a primary or secondary diagnosis when the provider documentation supports the specific condition described. Billable codes in ICD-10-CM are coded to the highest level of specificity available for the documented diagnosis. M90.611 is current for fiscal year 2026 and remains in the active CMS ICD-10-CM code set published by the National Center for Health Statistics.

Question 4

What is the V28 vs V24 difference for M90.611?

Accepted Answer

M90.611 does not map to a payment HCC under either the CMS-HCC V28 risk adjustment model or the older V24 model. V28 reached 100% phase-in for payment year 2026, replacing V24 which was used during the PY2024–PY2025 transition. Because neither model rewards M90.611 with a risk adjustment factor, it contributes zero to a Medicare Advantage beneficiary's RAF score in either version. Coders should check whether provider documentation supports a more specific child code that does map to a payment HCC.

Question 5

What should coders know when reporting M90.611?

Accepted Answer

This code requires documentation of the underlying neoplastic disease; code the primary malignancy separately Verify laterality is documented as right shoulder to ensure accurate code selection

M90.611

Is M90.611 an HCC code?

What This Code Means

Coding Tips

Code Hierarchy

Open M90.611 in the Interactive Encoder